Our Science

Expanding the universe of treatable diseases by harnessing the cell's natural mechanism for enhancing protein function

ENTAC™ drugs in action

At their core, ENTACs — enhancement-targeting chimeras — are molecular matchmakers. These small-molecule drugs bring together beneficial target proteins with enzymes called deubiquitylases, or DUBs, which are key regulators of protein function. DUBs work by selectively shortening or removing chains of a molecule called ubiquitin that are attached to proteins. Whether the target protein is in short supply, is in the wrong place within the cell, or has suboptimal activity, an ENTAC can be designed to recruit a DUB to fix the problem. By introducing each target to the right DUB, ENTACs enhance the function of these crucial proteins — many of which cannot be targeted with existing drugs — ultimately restoring the cell’s health.

ENTACs bring specific target proteins together with specific DUBs...

...allowing the DUB to shorten or remove the target's ubiquitin chain.

Specific DUBs remove ubiquitin subunits in specific ways...

...enhancing the function of target proteins in specific ways.

1 2 3 4

Encompass platform

Our proprietary end-to-end Encompass platform integrates powerful biological, chemical, and computational tools to:

Efficiently identify disease targets amenable to ENTAC intervention
Select an optimal DUB to address the specific target
Create specific ENTACs for each target-DUB pair

TARGET SELECTION

AI-driven target discovery and prioritization
Ubiquitinome toolbox
Genetic target-DUB interaction mapping

ENTAC DESIGN

ENTAC DESIGN

Structurally enabled drug design
Core linker library
ENTAC activity assays & modeling

DUB SELECTION

DUB biology atlas
DUB function toolbox
High affinity, non-inhibitory DUB ligands

Latest news & publications

06/23/2026 Press Releases

Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors

A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced proximity therapeutics. Houston's deep experience with protein degraders will be invaluable to supporting Entact’s development of ENTAC™ medicines, which leverage the same un...

02/08/2026 Publications Francesca Querques, Victoria Ciampani, Pei Yee Tey, Victoria D Kutilek, Elma Kadic, Michael J Clague, Sylvie Urbé

Targeted recruitment of USP15 enhances CTLA4 surface levels and restricts its degradation

09/17/2024 Press Releases

Entact Bio Appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer

Veteran drug developer and R&D leader with three decades of pharmaceutical and biotech experience to oversee development of targeted protein enhancement modality Watertown, MA, September 17, 2024 – Entact Bio, a company committed to improving the lives of patients by developing precision medicines that enhance the fu...

05/29/2024 Press Releases

Entact Bio Appoints Michael Gutch, Ph.D., as Chief Operating Officer

Veteran pharma and biotech executive with 20 years of operations and finance experience joins world-leading team advancing novel targeted protein enhancement modality Watertown, MA, May 29, 2024 – Entact Bio, the pioneer of precision medicines that enhance the function of beneficial proteins, today announced the appo...

See all news & publications